Aside from the establishment of thrombolysis with recombinant tissue plasminogen activator (rtPA), which has been implemented since 1996, seven randomized clinical trials have highlighted endovascular stroke treatment (EST) as a remarkable additional therapeutic option for patients with severe symptoms and large vessel occlusion (LVO) AIS4–6,22–29. The gene discussed is PLAT; the disease is Stroke.